ArticleNeuro-oncology advances
Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent IDH-wildtype glioblastoma has a poor prognosis, and no validated molecular biomarker guides second-line treatment choices. Because phosphatase and tensin homolog (PTEN) alterations are frequent in glioblastoma and may influence therapy resistance, we assessed their association with outcomes in patients with recurrence of IDH-wildtype glioblastoma. Methods: This is a retrospective study including consecutive adults with first recurrence of IDH-wildtype glioblastoma treated between 2019 and 2022 with regorafenib, nitrosoureas, or bevacizumab. Phosphatase and tensin homolog alterations were assessed by next generation sequencing. Overall survival (OS) was analyzed using Kaplan-Meier estimates and multivariable Cox models adjusted for clinically relevant covariates. An exploratory weighted analysis compared regorafenib and nitrosoureas in PTEN wild-type tumors. Results: Among 226 patients, 128 (57%) had PTEN alterations. The prevalence was higher in patients who received regorafenib (66%) than in those treated with nitrosourea (48%) or bevacizumab (55%). In univariate analyses, PTEN alteration was associated with shorter survival with regorafenib (median OS, 9.4 vs 17.0 months; hazard ratio [HR], 2.04; Conclusions: Phosphatase and tensin homolog alteration is a clinically relevant prognostic biomarker in recurrent IDH-wildtype glioblastoma and warrants prospective validation as a stratification factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.